FDA Clarifies the Term ‘Outsourcing Facility’ and Requirements for 503A Compounders

Drug Industry Daily
A A
As part of its increased focus on drug compounding, the FDA issued a final guidance clarifying the term “outsourcing facility” and detailing requirements for compounders operating under 503A that are next to an outsourcing facility.

To View This Article:

Login

Subscribe To Drug Industry Daily